Europe Blood Screening Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Europe Blood Screening Market Size

• The Europe blood screening market size was valued at USD 4.31 billion in 2025 and is expected to reach USD 8.58 billion by 2033, at a CAGR of 9.00% during the forecast period
• The market growth is largely fueled by increasing prevalence of blood-borne diseases, growing awareness around transfusion safety, and adoption of advanced diagnostic technologies across healthcare facilities
• Furthermore, rising regulatory emphasis on safe blood supply, coupled with the demand for high-throughput, automated, and accurate screening solutions in hospitals and blood banks, is positioning blood screening as a critical component of modern healthcare infrastructure. These factors are collectively driving the adoption of blood screening solutions, thereby significantly boosting the industry’s growth

Europe Blood Screening Market Analysis

• Blood screening, encompassing tests for infectious agents such as HIV, HBV, HCV, and syphilis, is increasingly critical for ensuring safe blood transfusions and maintaining high standards of public health across hospitals, blood banks, and diagnostic laboratories in Europe, driven by advancements in automated and high-throughput screening technologies
• The escalating demand for blood screening is primarily fueled by rising prevalence of blood-borne diseases, stringent regulatory requirements for transfusion safety, and the adoption of rapid, reliable, and multiplex testing platforms that reduce human error and turnaround time
• Germany dominated the Europe blood screening market with the largest revenue share of 38.5% in 2025, characterized by well-established healthcare infrastructure, strong government initiatives for safe blood supply, and the presence of major diagnostic and biotechnology companies, with substantial adoption of nucleic acid testing (NAT) and automated immunoassay platforms
• Poland is expected to be the fastest-growing country in the Europe blood screening market during the forecast period due to increasing investments in healthcare modernization, rising awareness about blood safety, and expansion of blood donation and transfusion services
• Nucleic acid testing segment dominated the blood screening market with a market share of 45.7% in 2025, driven by its high sensitivity, early detection capabilities, and growing adoption across centralized and regional blood screening centers

Report Scope and Europe Blood Screening Market Segmentation    

Europe Blood Screening Market Trends

Increased Accuracy Through Automation and Multiplex Testing

• A significant and accelerating trend in the Europe blood screening market is the adoption of automated high-throughput platforms and multiplex testing technologies, which allow simultaneous detection of multiple infectious agents from a single blood sample, improving both speed and accuracy
  • For instance, the Procleix Panther system integrates automated nucleic acid testing (NAT) with advanced software, enabling laboratories to process thousands of samples daily while reducing human error and turnaround time
• Automation in blood screening enhances workflow efficiency, reduces manual intervention, and supports real-time monitoring of sample processing, ensuring more reliable and consistent results. Furthermore, multiplex platforms allow blood banks to detect HIV, HBV, HCV, and other pathogens simultaneously, optimizing resources and enhancing safety
• The seamless integration of blood screening systems with laboratory information management systems (LIMS) and hospital databases facilitates centralized data management, allowing healthcare professionals to track results, identify trends, and manage transfusion safety more effectively
• This trend toward high-throughput, multiplex, and integrated screening solutions is fundamentally improving blood safety standards in Europe. Consequently, companies such as Grifols are developing automated NAT platforms with multiplex capabilities to ensure safer and faster blood screening
• The demand for automated and multiplex blood screening solutions is growing rapidly across hospitals, regional blood centers, and diagnostic laboratories, as healthcare providers increasingly prioritize efficiency, accuracy, and regulatory compliance
• In addition, cloud-based connectivity is gaining traction, allowing real-time sharing of screening results across healthcare networks, improving coordination and response to potential transfusion-transmissible infections

Europe Blood Screening Market Dynamics

Driver

Rising Prevalence of Blood-Borne Diseases and Regulatory Mandates

• The increasing incidence of transfusion-transmissible infections across Europe, coupled with strict regulatory requirements for blood safety, is a significant driver for the growing adoption of advanced blood screening technologies
  • For instance, in March 2025, Roche announced an upgrade to its Cobas NAT system to expand detection capabilities for emerging pathogens in donated blood, aiming to meet evolving European regulatory standards
• As governments and health authorities enforce stringent safety guidelines, blood banks and hospitals are compelled to adopt high-sensitivity testing platforms, ensuring safer transfusions and reducing risk of disease transmission
• Furthermore, the growing focus on early detection of infections and the need to maintain safe blood inventories are making blood screening an essential component of healthcare infrastructure across Europe
• The combination of rising disease prevalence, mandatory screening regulations, and increasing adoption of automated and high-throughput platforms is propelling the Europe blood screening market growth
• Increasing public-private partnerships and funding initiatives for blood safety programs are further incentivizing hospitals and blood centers to invest in advanced screening solutions
• Expanding awareness campaigns and training programs for healthcare personnel are also driving adoption, ensuring proper utilization of sophisticated blood screening technologies

Restraint/Challenge

High Cost and Infrastructure Limitations in Emerging Regions

• The relatively high cost of advanced blood screening systems, including automated NAT and multiplex platforms, poses a challenge for widespread adoption in smaller hospitals or emerging European markets with limited budgets
  • For instance, reports from smaller regional blood centers in Eastern Europe highlight budget constraints that delay the procurement of high-throughput screening instruments despite regulatory pressure
• Maintaining and calibrating sophisticated equipment requires specialized staff and infrastructure, which can be limited in developing regions or smaller facilities, constraining market penetration. Furthermore, the need for continuous supply of reagents and software updates adds ongoing operational costs, impacting affordability
• While some automated and compact platforms are becoming more cost-effective, the upfront investment for premium systems remains a barrier for price-sensitive laboratories and smaller blood centers
• Overcoming these challenges through cost-effective solutions, government subsidies, and training programs for staff will be crucial to expanding adoption and sustaining market growth across all European countries
• Variability in national regulatory frameworks across European countries can delay approvals and create compliance complexities for manufacturers and blood centers
• In addition, limited awareness and resistance to technology adoption among older staff in some blood banks can slow implementation of advanced automated and multiplex screening platforms

Europe Blood Screening Market Scope

The market is segmented on the basis of products and services, technology, disease type, and end user.

• By Products and Services

On the basis of products and services, the Europe blood screening market is segmented into reagents and kits, instruments, and software and services. The reagents and kits segment dominated the market with the largest revenue share in 2025, driven by the recurring need for high-quality consumables in testing laboratories and blood banks. Reagents and kits form the core of any blood screening process, enabling accurate detection of pathogens such as HIV, HBV, and HCV, and are critical for compliance with regulatory standards. The segment benefits from constant innovation, including multiplex assay kits and automated reagent solutions, which improve testing throughput and reduce human error. High adoption in hospitals, diagnostic centers, and blood banks ensures a steady demand for reagents and kits across Europe. Leading companies continuously invest in research and development to expand the range of high-sensitivity kits for emerging pathogens, further strengthening the segment’s market position.

The instruments segment is anticipated to witness the fastest growth from 2026 to 2033, fueled by the increasing adoption of automated, high-throughput platforms such as nucleic acid testing (NAT) systems and immunoassay analyzers. Instruments provide enhanced accuracy, speed, and standardization, reducing manual intervention and improving overall laboratory efficiency. The growing trend of centralizing blood screening laboratories and upgrading outdated equipment in hospitals and regional centers is driving the uptake of modern screening instruments. In addition, instruments integrated with software solutions allow real-time monitoring, data management, and reporting, further supporting their rapid adoption.

• By Technology

On the basis of technology, the market is segmented into nucleic acid test (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assay, next-generation sequencing (NGS), and others. The nucleic acid testing segment dominated the market with the largest revenue share of 45.7% in 2025, owing to its high sensitivity, early detection capability, and ability to reduce the risk of transfusion-transmissible infections. NAT is widely adopted in hospitals and blood banks for screening large volumes of blood donations, ensuring compliance with stringent European safety regulations. The segment benefits from continuous technological advancements, such as automated NAT platforms and multiplex testing capabilities. Its dominance is further reinforced by the growing prevalence of blood-borne diseases and the critical need for accurate and reliable blood safety testing.

Rapid tests are expected to witness the fastest CAGR from 2026 to 2033, driven by the increasing demand for point-of-care testing and quick results, particularly in remote or smaller healthcare facilities. Rapid tests are simple, cost-effective, and provide immediate preliminary results, which are crucial for urgent clinical decisions or donor screening in high-volume centers. Their portability and ease of use make them suitable for on-site screening in blood donation camps and outpatient facilities. The segment is also benefiting from technological innovations that improve sensitivity and specificity, making rapid tests increasingly reliable.

• By Disease Type

On the basis of disease type, the Europe blood screening market is segmented into respiratory diseases, diabetes mellitus, oncology, cholesterol, HIV/AIDS, cold and flu, infectious diseases, and others. Infectious diseases dominated the market with the largest revenue share in 2025, driven by the ongoing need to screen blood for pathogens such as HIV, HBV, HCV, syphilis, and emerging viral threats. Blood banks and hospitals prioritize infectious disease screening to ensure transfusion safety and comply with European regulatory mandates. The segment benefits from increasing awareness of transfusion-transmissible infections, technological advancements in detection methods, and the rise of centralized blood screening programs. Continuous updates in screening protocols for emerging pathogens further reinforce its market dominance.

The HIV/AIDS segment is expected to witness the fastest growth from 2026 to 2033, fueled by increasing public health initiatives, awareness campaigns, and targeted donor screening programs. The high sensitivity of modern NAT and ELISA-based assays for HIV detection encourages rapid adoption in blood banks, diagnostic laboratories, and hospitals. Growing investments in early detection and prevention programs are also contributing to the segment’s accelerated growth. Furthermore, the emphasis on reducing transfusion-related HIV transmission supports the expansion of specialized testing for this disease across Europe.

• By End User

On the basis of end user, the Europe blood screening market is segmented into diagnostic centers, blood banks, hospitals, clinics, and ambulatory surgical centers. Blood banks dominated the market with the largest revenue share in 2025, driven by their critical role in ensuring safe blood supply and compliance with national and European safety regulations. Blood banks require regular and high-volume screening of donated blood, relying heavily on advanced technologies such as NAT, ELISA, and multiplex testing. Continuous investment in infrastructure, automation, and staff training ensures efficient operations and high safety standards, further strengthening their market dominance.

Diagnostic centers are expected to witness the fastest CAGR from 2026 to 2033, fueled by the increasing outsourcing of blood screening services, rising patient awareness, and expansion of private laboratory networks across Europe. Diagnostic centers offer specialized services for multiple diseases, rapid testing capabilities, and advanced instrumentation, meeting growing demand from hospitals, clinics, and smaller healthcare facilities. In addition, partnerships between diagnostic centers and hospitals enable widespread adoption of modern blood screening technologies, accelerating market growth.

Europe Blood Screening Market Regional Analysis

• Germany dominated the Europe blood screening market with the largest revenue share of 38.5% in 2025, characterized by well-established healthcare infrastructure, strong government initiatives for safe blood supply, and the presence of major diagnostic and biotechnology companies
• The country prioritizes adoption of advanced blood screening technologies such as nucleic acid testing (NAT) and automated immunoassay platforms, enabling rapid, accurate, and reliable detection of infectious agents in donated blood
• This widespread adoption is further supported by strong government initiatives, high healthcare spending, the presence of major diagnostic and biotechnology companies, and growing awareness of transfusion-transmissible infections among healthcare providers and the public

The Germany Blood Screening Market Insight

The Germany blood screening market captured the largest revenue share of 38.5% in Europe in 2025, driven by its advanced healthcare infrastructure, stringent regulatory standards, and strong focus on transfusion safety across hospitals and blood banks. Hospitals and blood centers are increasingly adopting automated nucleic acid testing (NAT) platforms, high-throughput immunoassays, and multiplex testing to ensure rapid and accurate detection of infectious agents. The market is further supported by continuous government initiatives, high healthcare spending, and the presence of major diagnostic and biotechnology companies. Integration of laboratory information management systems (LIMS) with automated screening instruments enhances workflow efficiency and compliance. Increasing awareness of transfusion-transmissible infections among healthcare providers and the public further drives adoption. Technological innovation and emphasis on reliable, privacy-focused testing solutions continue to strengthen the Germany market position.

U.K. Blood Screening Market Insight

The U.K. blood screening market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing awareness of transfusion safety and adoption of advanced diagnostic technologies. Hospitals and blood banks are implementing high-sensitivity NAT, ELISA, and multiplex testing platforms to improve screening accuracy and turnaround time. Regulatory compliance and standardization of blood safety protocols are key factors stimulating adoption. The U.K.’s well-developed healthcare system, expanding private diagnostic laboratories, and high public health awareness are supporting market growth. The rising prevalence of blood-borne diseases further emphasizes the need for accurate and reliable blood screening solutions. Continuous innovation in automated testing systems and integration with digital data management enhances efficiency and strengthens the market.

France Blood Screening Market Insight

The France blood screening market is expected to expand at a significant CAGR during the forecast period, fueled by strong regulatory frameworks, growing healthcare expenditure, and increasing focus on transfusion safety. Blood banks and hospitals are adopting automated NAT and ELISA platforms to ensure early detection of HIV, HBV, HCV, and other infectious agents. The market benefits from government programs promoting safe blood supply and continuous modernization of healthcare infrastructure. Hospitals are increasingly integrating screening systems with digital management tools to streamline operations and ensure compliance. Rising public awareness of transfusion-transmissible infections further drives the adoption of advanced screening technologies. Technological advancements in multiplex testing and rapid diagnostics are strengthening the France market position.

Poland Blood Screening Market Insight

The Poland blood screening market is anticipated to grow at the fastest CAGR in Europe during the forecast period, driven by increasing investments in healthcare infrastructure and modern diagnostic technologies that support enhanced blood safety. Rising prevalence of infectious diseases and government initiatives to strengthen early detection and screening have expanded demand for advanced assays and molecular screening platforms throughout public and private healthcare facilities. Public awareness campaigns on blood safety and regular donation programs are boosting screening volumes at regional blood banks and hospitals, emphasizing the need for reliable pathogen testing. Adoption of molecular diagnostics and point‑of‑care rapid tests is increasing as laboratories seek higher accuracy and quicker turnaround times for HIV, HBV, HCV, and other transfusion‑transmissible infection screening.

Europe Blood Screening Market Share

The Europe Blood Screening industry is primarily led by well-established companies, including:

• BIOMÉRIEUX (France)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbott (U.S.)
• Thermo Fisher Scientific Inc (U.S.)
• BD (U.S.)
• Bio‑Rad Laboratories, Inc. (U.S.)
• Danaher (U.S.)
• Beckman Coulter, Inc. (U.S.)
• Grifols, S.A. (Spain)
• Siemens Healthineers AG (Germany)
• DiaSorin S.p.A. (Italy)
• Eurofins Scientific (Luxembourg)
• Nelson Labs (Belgium)
• Unilabs (Spain)
• Nordic Laboratories (U.K.)
• LocalPCR (U.K.)
• Wren Healthcare (U.K.)
• Tempus600 (Finland)
• On Point Testing (Norway)
• Age Labs (Norway)

What are the Recent Developments in Europe Blood Screening Market?

• In December 2025, Guardant Health and Policlinico Gemelli launched an in‑house liquid biopsy blood testing service in Rome, Italy, using Guardant360® CDx blood‑based cancer profiling technology expanding local access to precision oncology diagnostics and genomic screening in a major European hospital system
• In September 2025, the European Centre for Disease Prevention and Control (ECDC) published the first technical guidelines under new EU safety regulation (Regulation (EU) 2024/1938) for HIV screening and safety of blood and other substances of human origin across the EU/EEA harmonizing blood screening standards continent‑wide
• In April 2025, ECDC released a survey report detailing HIV testing strategies for blood, tissue and cell donors across the EU/EEA, highlighting widespread use of molecular methods such as nucleic acid testing (NAT) alongside serological assays across member states
• In June 2024, GFE announced the launch of PoET® CMV, the first CE IVDR‑certified nucleic acid amplification technology (NAT) assay for screening donated blood for cytomegalovirus (CMV) under the new European In‑Vitro Diagnostic Regulation, enhancing pathogen detection and reducing the risk of transfusion of infected blood or blood components across EU blood banks
• In June 2022, Grifols’ Procleix Plasmodium Assay received CE marking in Spain the first CE‑marked automated nucleic acid test (NAT) for malaria in blood screening, enhancing pathogen safety in blood banks and reducing transfusion‑transmitted malaria risk

SKU-1887